Organon and Co (OGN) News

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

Full year 2024 revenue of $6.4 billion, up 2% as-reported and 3% at constant currency Full year 2024 diluted earnings per share of $3.33 and...

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its fourth quarter and full year 2024 financial...

Form 8-K - Current report

Form 8-K - Current report

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to...

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

EFFICACY: In the pivotal studies, ADORING 1 and ADORING 2, up to 46% of patients on VTAMA cream achieved vIGA-AD™ treatment success at Week 8...

Form 8-K - Current report

Form 8-K - Current report

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]